LP Attorney Cameron Stephenson Appointed to Plaintiffs’ Executive Committee in GLP-1 Vision Loss MDL February 24, 2026 On February 23, 2026, the United States District Court for the Eastern District of Pennsylvania appointed Cameron Stephenson, a shareholder at Levin Papantonio, to the Plaintiffs’ Executive Committee in the consolidated federal litigation involving glucagon-like peptide-1 (GLP-1) receptor agonist drugs and alleged non-arteritic anterior ischemic optic neuropathy (NAION). In a case management order, Judge Karen […] Read More
Federal Court Creates New MDL for Ozempic and Other GLP-1 Drugs Linked to Vision Loss (NAION) December 17, 2025 Federal Court Creates New MDL for Ozempic and Other GLP-1 Drugs Linked to Vision Loss (NAION) The U.S. Judicial Panel on Multidistrict Litigation has ordered the creation of a new federal multidistrict litigation consolidating lawsuits alleging that popular GLP-1 receptor agonist drugs caused patients to suffer serious vision injuries, including non-arteritic anterior ischemic optic neuropathy, […] Read More
Do Ozempic and Other Weight-Loss Drugs Cause Vision Loss? February 21, 2025 More Drug Injury News Read More
Levin Law
Levin Law